Stada Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>SA</div>
STDAF -- USA Stock  

USD 110.42  0.00  0.00%

6% of traded otc stocks are less volatile than Stada, and 99% of all traded equity instruments are likely to generate higher returns over the next 60 trading days. While some of us are excited about healthcare space, it makes sense to digest Stada Arzneimi in greater detail to make a better estimate of its risk and reward. We will cover the possibilities of Stada Arzneimi's current volatility to continue through December.
Published over a week ago
View all stories for Stada Arzneimi | View All Stories
Will Stada Arzneimi (OTC:STDAF) low risk outlook last untill December?
Stada Arzneimi classifies itself under Healthcare sector and is part of Drug Manufacturers?Specialty & Generic industry.
Volatility is a rate at which the price of Stada Arzneimi or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Stada Arzneimi may increase or decrease. In other words, similar to Stada's beta indicator, it measures the risk of Stada Arzneimi and helps estimate the fluctuations that may happen in a short period of time. So if prices of Stada Arzneimi fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is Stada Arzneimi's Liquidity

Stada Arzneimi financial leverage refers to using borrowed capital as a funding source to finance Stada Arzneimi Namen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Stada Arzneimi financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Stada Arzneimi's total debt and its cash.

How Stada utilizes its cash?

To perform a cash flow analysis of Stada Arzneimi, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Stada Arzneimi is receiving and how much cash it distributes out in a given period. The Stada Arzneimi cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Breaking down Stada Arzneimi Indicators

This firm reported the revenue of 2.69 B. Net Income was 252.03 M with profit before overhead, payroll, taxes, and interest of 1.37 B.

Stada Arzneimi possible recoup in December

The coefficient of variation is down to 8789.18 as of today. Stada Arzneimi Namen exhibits very low volatility with skewness of 1.12 and kurtosis of 33.07. However, we advise investors to further study Stada Arzneimi Namen technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Stada Arzneimi

When is the right time to buy or sell Stada Arzneimi Namen? Buying stocks such as Stada Arzneimi isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. Taking everything into account, as of the 14th of November 2020, our analysis shows that Stada Arzneimi moves indifferently to market moves. The firm is overvalued and projects below average probability of distress for the next 2 years. Our actual 30 days buy vs. sell advice on the firm is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Stada Arzneimi Namen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com